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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with a dismal prognosis. 
However, while most patients die within the first year of diagnosis, very rarely, a few patients can 
survive for more than10-years. Better understanding the molecular characteristics of the pancreatic 
adenocarcinomas from these very long-term survivors (VLTS) may provide clues for personalized 
medicine and improve current pancreatic cancer treatment. To extend our previous investigation, 
we examined the proteomes of individual pancreas tumor tissues from a group of VLTS patients 
(survival ≥10 years) and short-term survival patients (STS, survival <14 months). With a given 
analytical sensitivity, the protein profile of each pancreatic tumor tissue was compared to reveal 
the proteome alterations that may be associated with pancreatic cancer survival. Pathway analysis 
of the differential proteins identified suggested that MYC, IGF1R and p53 were the top three 
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
Corresponding author: Ru Chen, PhD, Department of Medicine, University of Washington, Seattle, WA 98195, 
ruc@medicine.washington.edu. 
Disclosure. The authors declare no duality of interest.
Supplementary information is available at Laboratory Investigation's website.
HHS Public Access
Author manuscript
Lab Invest. Author manuscript; available in PMC 2015 July 01.
Published in final edited form as:
Lab Invest. 2015 January ; 95(1): 43–55. doi:10.1038/labinvest.2014.128.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
upstream regulators for the STS associated proteins, and VEGFA, APOE, and TGFβ-1were the top 
three upstream regulators for the VLTS associated proteins.
Immunohistochemistry analysis using an independent cohort of 145 PDAC confirmed that the 
higher abundance of ribosomal protein S8 (RPS8)and prolargin (PRELP)were correlated with STS 
and VLTS, respectively. Multivariate Cox analysis indicated that “High-RPS8 and Low-
PRELP”was significantly associated with shorter survival time (HR=2.69, 95% CI 1.46-4.92, 
p=0.001).In addition, galectin-1, a previously identified protein with its abundance aversely 
associated with pancreatic cancer survival, was further evaluated for its significance in cancer-
associated fibroblasts. Knockdown of galectin-1 in pancreatic cancer-associated fibroblasts 
dramatically reduced cell migration and invasion.The results from our study suggested that 
PRELP, LGALS1 and RPS8 might be significant prognostic factors, and RPS8 and LGALS1 
could be potential therapeutic targets to improve pancreatic cancer survival if further validated.
Keywords
pancreatic cancer; pancreatic ductal adenocarcinoma (PDAC); prognostics; biomarker; galectin-1 
(LGALS1); prolargin (PRELP); 40S ribosomal protein S8 (RPS8); proteomics; mass 
spectrometry; immunohistochemistry; tissue microarray
The prognosis of pancreatic ductal adenocarcinoma (PDAC) is extremely poor: the majority 
of patients die within the 6 months of diagnosis, and only 6% of patients survive for five 
years1. At the time of diagnosis, most patients have surgically unresectable disease. For the 
patients who undergo surgical resection, the clinical outcome is considerably better, with 5-
year survival rates of up to 20% in some studies 2-11. In very rare situations, some patients 
can survive for a very long-term (VLTS, defined as patients with ≥10-year survival 
following resection) and are essentially cured of their disease. There are some published 
studies which have identified VLTS of histologically validated PDAC, usually at a 
frequency less than 5% in most series2, 3, 10, 12. Surprisingly, patients with aggressive 
diseases such as T3-T4 lesions and involvement of lymph node were also presented in these 
VLTS cohorts, suggesting that the basis of VLTS in PDAC extends beyond simply resecting 
node-negative localized cases, but might indicate an intrinsic molecular phenotype of such 
tumors13.
Several clinicopathological characteristics have been demonstrated to have significant effect 
on long-term survival including: small tumor size (<2 cm), negative lymph node status, 
negative resection margin (i.e. R0) and differentiation grade14. However, the molecular 
characteristics relating to long term-survival of PDAC are poorly understood. Using a 
PDAC survival tissue microarray, a study evaluated 13 putative biomarkers selected from 
the literature, and identified mucin 1 and mesothelin as biomarkers for predicting 
aggressiveness of pancreatic cancer biology, outperforming pathologic features and other 
putative biomarkers15. In our previous efforts, using pooled samples we discovered that the 
abundance of stromal galectin 1 (LGALS1) was adversely associated with survival from 
PDAC, while the abundance of prolargin (PRELP), osteoglycin (OGN) and rheumatoid 
factors D5 light chain (V<kappa>3) were higher in the pancreatic tumor tissues of VLTS 
relative to STS13. Immunohistochemistry (IHC) analysis of pancreatic tumor tissues using 
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two independent cohorts confirmed that an increased/strong abundance of galectin-1, a T-
cell immune-modulator and metastasis-related protein, in the cancer stroma was a negative 
indicator of pancreatic cancer survival13. For PRELP, contradictorily, a recent study 
suggested that the high abundance of PRELP was associated with shorter pancreatic cancer 
survival16. While various factors could influence the observations in different studies, the 
role of PRELP in pancreatic cancer survival remains uncertain and warrants further 
investigation.
In the current study, we sought to expand our understanding of the proteome characteristics 
associated with pancreatic cancer survival by analyzing the individual cancerous tissues 
from VLTS and STS patients using a label-free proteomics approach. Functional protein 
annotation and pathway analysis of the differential proteins associated with VLTS and STS 
aided in the characterization of the mechanisms underlying survival. While a comprehensive 
interpretation of the data obtained will require additional information beyond this 
investigation, selected exploration of a few interesting proteins are presented here. IHC 
validation was performed using a clinically annotated tissue microarray (TMA) to examine 
the significance of the protein targets in the context of PDAC survival. In addition, a 
functional study was performed to evaluate the effects of galectin-1 on the metastatic 
behavior of cancer-associated fibroblasts.
Methods and Materials
Patients and specimens
This study was approved by the Human Subjects Division of the University of Washington, 
the Internal Review Board (IRB) of the University of California at UCLA, and the IRB of 
the Johns Hopkins Medical Institutions. Very long-term survivors (VLTS) and short-term 
survivors (STS) were identified as survivors of PDAC for ≥10 years and <14 months, 
respectively, following surgical resection. Before inclusion, the histology was reviewed for 
all of the identified VLTS and STS cases from Johns Hopkins by two experts in pancreatic 
pathology (RHH and AM), in order to confirm the diagnosis of PDAC and exclude the 
possibility of confounding lesions like ampullary cancers and/or intraductal papillary 
mucinous neoplasm (IPMN). Five VLTS and five STS cases were matched by tumor stage 
and grade for proteomic analysis. These tumors were obtained prior to treatment and thus 
the proteomes represented the naïve state of the adenocarcinoma. The changing standards 
for adjuvant chemotherapy over the past 15 years precluded us from matching cases by type 
of treatment received.The validation cohort was from UCLA with 145 PDAC cases 
constructed on a previously described TMA17. The clinicopathological and survival 
information for each patient were obtained from UCLA surgical database of pancreatic 
patients. Survival analysis of the UCLA cohort was limited to overall survival, which was 
determined by review of clinical records and search of the Social Security Death Index. 
Survival intervals were calculated from date of surgery to date of confirmed death or last 
patient contact. The clinicopathological and survival information of the PDAC cases 
included in our study are provided in Table 1.
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Protein extraction from formalin-fixed paraffin-embedded tissue
VLTS of pancreatic cancer is rare, and the availability of fresh frozen tissue specimens from 
these VLTS patients is therefore extremely scarce. The current study made use of the 
commonly preserved format of clinical specimens (i.e. formalin-fixed paraffin-embedded 
(FFPE)) for comparative proteomics analysis18. Extraction of proteins from FFPE tissue 
were carried out as described in our previous study18. Briefly, unstained 15 μm sections of 
FFPE tissue were deparaffinized and rehydrated. The corresponding H&E slides were 
examined under the microscope to delineate the areas with highest neoplastic cellularity 
(including both PDAC epithelium and associated stroma), while excluding obvious areas of 
non-neoplastic pancreatic acinar tissues and inflammatory infiltrates.An equivalent of 1 
cm×1 cm×15 μm amount of deparaffinized tissue samples were scraped from each slide and 
transferred into 300 μl lysis solution of 70% 50 mM ammonium bicarbonate and 30% 
acetonitrile, using sterile blades and needle tips. The lysates were then incubated at 90°C for 
30 minutes followed by 60°C for 120 minutes. The samples were sonicated for 2 minutes 
followed by 1 minute incubation on ice. The sonication and ice incubation process was 
repeated twice more. The homogenized samples were incubated at 60°C for 1 hr, followed 
by a second sonication step.
Sample preparation for proteomics analysis
The protein lysates were digested with sequencing-grade trypsin (Promega, Madison, WI) at 
a trypsin to protein ratio of 1:50 at 37°C for 18 hours. The digested samples were 
centrifuged at 1500×g for 10 minutes and the supernatants were collected. The protein 
digests were reduced with 10 mM dithiothreitol (DTT) at 60°C for 60 minutes then 
incubated with 25 mM iodoacetamide at room temperature in the dark for 30 minutes for 
cysteine alkylation. The samples were then purified with C18 columns (UltraMicroSpin 
Column/Vydac C18 silica, The Nest Group, Inc., Southborough, MA), dried down and 
stored at −20°C until mass spectrometric analysis.
LC MS/MS analysis
An LTQ-Orbitrap hybrid mass spectrometer (Thermo Fisher Scientific, Waltham, MA) 
coupled with a nano-flow HPLC (Eksigent Technologies, Dublin, CA) was used in this 
study. A 2 μg sample of each case was injected for the mass spectrometric analysis. The 
samples were first loaded onto a 1.5 cm trap column (IntegraFrit 100 μm, New Objective, 
Woburn, MA) packed with Magic C18AQ resin (5 μm, 200 Å particles; Michrom 
Bioresources, Auburn, CA) with Buffer A (water with 0.1% formic acid) at a flow rate of 3 
uL/minute. The peptide samples were then separated by an 27 cm analytical column 
(PicoFrit 75 μm, New Objective) packed with Magic C18AQ resin (5 μm, 100 Å particles; 
Michrom Bioresources) followed by mass spectrometric analysis. A 90-minute linear LC 
gradient was used as follows: 5% to 7% Buffer B (acetonitrile with 0.1% formic acid) versus 
Buffer A over 2 minutes, then to 35% over 90 minutes, then to 50% over 1 minute, hold at 
50% for 9 minutes, change to 95% over 1 minute, hold at 95% for 5 minutes, drop to 5% 
over 1 minute and recondition at 5%. The flow rate for the peptide separation was 300 nL/
minute. For MS analysis, a spray voltage of 2.25 kV was applied to the nanospray tip. The 
mass spectrometry experiment was performed using data-dependent acquisition with a m/z 
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range of 400–1800, consisting of a full MS scan in the Orbitrap followed by up to 5 MS/MS 
spectra acquisitions in the linear ion trap using collision induced dissociation (CID). Other 
mass spectrometer parameters include: isolation width 2 m/z, target value 1e4, collision 
energy 35%, max injection time 100 ms. Lower abundance peptide ions were interrogated 
using dynamic exclusion (exclusion time 45 seconds, exclusion mass width −0.55 m/z low 
to 1.55 m/z high). A charge state screen was used, allowing for MS/MS of any ions with 
identifiable charge states +2, +3, and +4 and higher. The samples were analyzed in duplicate 
with random order using the identical instrument conditions.
Proteomics data analysis
Raw machine output files from all MS runs were converted to mzXML files and searched 
with X!Tandem19 configured with the k-score scoring algorithm20, against version 3.69 of 
the human International Protein Index (IPI) database. The search parameters were as 
follows: enzyme, trypsin; maximum missed cleavages, 1; fixed modification, 
carboxamidomethylation on cysteine; potential modification, oxidization on methionine; 
parent monoisotopic mass error, 2.5Da. Peptide identifications were assigned probability by 
PeptideProphet 21, and all identifications with an assigned probability <0.95 were discarded 
(estimated false discovery rate varied per experimental run in the range 0.006-0.007). 
Protein inference were assigned by ProteinProphet 22 using the peptides with probability 
scores ≥ 0.95. Any proteins with only one spectrum identified in one group and none in the 
other group were excluded from ratio calculation and subsequent analysis.The comparative 
analysis between the VLTS and STS was achieved using spectral counts of all the peptides 
in each protein/protein group. Both replicate data were included in the data analysis as 
averaging the spectral counts from the duplicate experiments reduces the technical 
variations. The protein ratio between VLTS group and STS group was calculated using the 
total spectral counts of 5 VLTS samples divided by the total spectral count of 5 STS 
samples.
Functional annotation, enrichment and pathway analysis
The enrichment of the biological processes was assessed by using The Database for 
Annotation, Visualization and Integrated Discovery (DAVID) v6.7 23. The pathway analysis 
was performed using ingenuity pathways analysis (IPA, Ingenuity Systems). The proteins 
that had a minimum of 2-fold abundance change between VLTS and STS groups were 
uploaded to IPA to identify upstream regulators significant to the dataset.
IHC analysis
Paraffin-embedded, formalin-fixed TMA block was sectioned at 4 μm onto charged slides 
and deparaffinized, processed for heat-induced epitope retrieval in 0.01mol/L citric acid 
buffer, pH 6.0 for 15 minutes in a vegetable steamer, followed by incubation with primary 
antibody against prolargin (Epitomics) or RPS8 (Proteintech) with 1:100 dilution incubation 
at room temperature for 1 hour. The LSAB+ HRP System (Dako, Carpinteria, Calif) was 
used for visualization. Three separate 1.0 mm cores for each annotated tumor in the TMA 
were independently scored by 2 blinded observers using semiquantitative histoscores (range 
0–300). Histoscores were the product of staining intensity (0–3) and the percentage of tumor 
cells staining at that intensity (0–100). If any core's histoscore differed by more than 30 
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points between observers, a revised score was assigned by consensus evaluation. Median 
histoscore of both observers was used for analysis.
Cell culture & stable transfection
Human cancer associated fibroblast cell line was prepared by the outgrowth method. Fresh 
tissue was obtained from residual pancreatic adenocarcinoma specimen from one patient 
undergoing primary surgical resection at University of Michigan. The human sample was 
obtained in accordance with the policies and practices of the Institutional Review Board of 
the University of Michigan. Briefly, tumor sample was minced and seeded in six-well plates 
containing 15% FBS/DMEM, L-glutamine(2 mmol/L), penicillin/streptomycin, and 
amphotericin. After 5 days, cells were able to grow out from the tissue clumps. Medium was 
changed every 3 days. Cells were maintained at 37°C in a humidified atmosphere of 5% 
CO2. When fibroblast cells grew to confluence, cells were trypsinized and passaged.The 
identification of fibroblast cell was determined by immunohistochemistry for αSMA, 
vimentin, PDGFR and FAP. The contamination of immunocytes and tumor cells were 
excluded by CD45 and CK19, respectively.
Galectin-1 knockdown cells were generated by stable transfection of galectin-1 shRNA 
(Qiagen #KH19360P) using Attractene Transfection Reagent (Qiagen) and selection with 
puromycin as per manufacturer's suggested protocol. Knockdown was confirmed by 
immunofluorescence and Western blot analysis using anti-galectin1 antibody (R&D 
AF1152) as per manufacturer's instructions. GAPDH was used as a loading control for 
Western blots.
Wound healing and Invasion assays
For wound healing, cells were grown to confluence on glass coverslips. Cells were manually 
wounded with a pipet tip. 24 hours later, cells were fixed and mounted onto slides with 
Prolong Gold plus DAPI (Invitrogen). Images were taken with a Leica DMLB microscope 
equipped with a Diagnostic Instruments Color Mosaic camera and software. Invasion assays 
were performed as described24.
Statistical analysis
All statistics were performed using SPSS, version 20.0, for Windows. Chi-square tests were 
used to compare dichotomized IHC groups against baseline clinicopathologic factors. 
Univariate Cox regression was performed to evaluate the prognostic significance of 
individual variables. Kaplan-Meier survival curves were analyzed by log rank 
test.Multivariate analysis was performed by stepwise Cox analysis with backward selection 
using the Akaike Information Criterion. The level of significance for all tests was defined as 
α=0.05.
Results
Proteomics analysis
Five pathologically and clinically well-characterized samples from each group of VLTS and 
STS were included and analyzed in duplicate. The samples were interrogated in a random 
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order using the same reversed-phase analytical column, LC gradient and mass spectrometer 
parameters. Using only the peptides identified with a PeptideProphet probability score ≥0.95 
(FDR < 1%), 1050 non-redundant proteins (based on gene symbol) was identified. To 
evaluate the reproducibility of the platform, all 10 samples analyzed were combined to 
assess the correlation of peptide intensity between two replicate runs. The ion intensity of 
the peptides in each analysis was plotted versus each other. A high correlation of the peptide 
intensities between the replicates was observed (Spearman R=0.95) (Supplemental Figure 
1), indicating a robust technical reproducibility.
Proteins associated with pancreatic cancer survival
For each protein identified, the protein ratio between VLTS and STS were quantified by 
calculating the ratio of total spectral counts between all 5 VLTS cases and all 5 STS 
cases.The spectral count information could be found in Supplemental Table 1. For the 
proteins that were detected in VLTS group, but not in STS group, the ratio of VLTS vs STS 
was assigned 100; and for the proteins that were only detected in STS group, the ratio of 
VLTS vs STS was assigned 0.01. Using 2-fold ratio as a threshold, 332 differentially 
expressed proteins between VLTS and STS were identified, including 139 proteins with ≥2-
fold increase in abundance in VLTS group (designated as “proteins associated with VLTS 
group”), and 193 proteins with ≥2-fold abundant increase in STS group (designated as 
“proteins associated with STS group”). Figure 1 shows the distribution of protein ratios 
(natural log-transformed) calculated between the VLTS and STS groups, excluding the 
proteins with a ratio with 0.01 or 100. Notably, the differentially expressed proteins 
identified in this study are relative between VLTS and STS, and many of them were found 
frequently over-expressed in pancreatic tumor tissues when compared to normal 
pancreas18, 25-27.
Functional enrichment and upstream regulation networks
To further characterize functional clusters of the proteins associated with PDAC survival 
groups, we uploaded the VLTS and STS survival-associated proteins onto DAVID online 
database for enrichment analysis23, 28. The enriched protein groups associated with STS and 
VLTS are summarized in Table 2. For STS associated differential proteins, the most 
significantly enriched protein cluster was Cytoskeleton Proteins, with 30 cytoskeleton 
proteins more abundantly associated with STS group. Proteins in this cluster were involved 
in cellular movement, cell division, endocytosis, movement of organelles, and maintenance 
of cell shape. The second enriched cluster of the STS associated proteins was 
Ribonucleoprotein Complex/Protein Biosynthesis, with 31 differential proteins included in 
this functional cluster. Within this cluster, there were proteins involved in nucleoporins, 
translational elongation, ribosomal proteins and protein biosynthesis. For VLTS associated 
differential proteins, the most significantly enriched cluster was copine proteins. Copines are 
Ca2+-dependent phospholipid-binding proteins that are thought to be involved in 
membrane-trafficking in response to intracellular calcium increase29. Eight copine proteins 
were more abundantly expressed in VLTS group. The second enriched cluster of VLTS 
associated proteins was Mitochondrion. Nineteen mitochondrial proteins were more 
abundantly expressed in VLTS group, including mitochondrial solute carrier proteins, 
mitochondrial membrane and matrix proteins, and other enzymes involved in cellular 
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respiration. Both the STS and VLTS associated proteins had an enriched cluster of 
Generation of Precursor Metabolites and Energy. But there were differences within this 
cluster regarding the survival-related proteins that were identified. The 10 VLTS associated 
proteins in this cluster were mostly mitochondrial proteins involved in oxidation and 
reduction process, while only 5 out of the 14 STS associated proteins were mitochondrial.
Upstream regulation network
To reveal potential pathways involved in pancreatic cancer survival, the Ingenuity Pathway 
Analysis (IPA) was used for upstream regulator analysis. The top three upstream regulators 
for the STS associated proteins were MYC, insulin-like growth factor 1 receptor (IGF1R) 
and TP53 (Figure 2A). MYC is a transcription factor that controls expression of numerous 
genes that govern cell proliferation, cell growth, cell differentiation and apoptosis. In our 
previous tissue proteomics studies, c-MYC was identified as a significant regulator 
implicating in pancreatic cancer, chronic pancreatitis, as well as precancerous 
PanIN318, 25, 27. In the current study, 25 STS associated proteins were regulated by MYC. 
IGF1R plays a crucial role in tumor transformation by regulating cell growth and survival. 
Eleven STS associated proteins were downstream of IFG1R pathways, five of which were 
also regulated by MYC. Tumor suppressor gene p53 is frequently mutated or deleted in 
pancreatic cancer. The protein product of p53 gene plays a pivotal role monitoring cellular 
repair and apoptosis in response to genetic damage or metabolite disorder. Twenty-four STS 
associated proteins were regulated by p53 protein. In connection with the other two 
upstream regulators MYC and IGF1R, the top three upstream regulators and their 
downstream targets (48 STS associated proteins) formed a cross-talk network involving two 
essential traits of cancer cells: proliferation and apoptosis. The top three upstream regulators 
for VLTS associated proteins were vascular endothelial growth factor A (VEGFA), 
apolipoprotein E (APOE) and TGF-β1, regulating 10, 9, and 24 VLTS associated proteins 
respectively (Figure 2B). These three upstream regulators linked 35 VLTS associated 
proteins in a network that regulated angiogenesis (VEGFA), cholesterol regulation (APOE) 
and proliferation, differentiation, survival and apoptosis (TGF-β1). While the information 
revealed by IPA is informative and consistent with our understanding of pancreatic 
tumorigenesis, much work is needed to experimentally investigate these molecular events 
that can potentially influence pancreatic cancer survival.
Correlation of prolargin with longer pancreatic cancer survival
Prolargin (PRELP) was one of the differential proteins associated with VLTS identified in 
our previous study13. Based on the proteomic data,overall, PRELP was 3.3 fold more 
abundant in the tumor tissues of the VLTS group compared to the STS group. The PRELP 
protein was detectable in all 5 VLTS cancer samples, with spectral counts ranging from 
9-23. In contrast, PRELP was marginally detectable in 4 of the 5 STS samples with much 
lower spectral count number, ranging from 1-7 (Figure 3A). The spectral counts of PRELP 
peptides were significantly higher in the long-term survival group than short-term survival 
group (p=0.010).
IHC analysis was performed on tissue sections from independent pancreatic cancer samples 
(UCLA cohort), constructed into a tissue microarray. The UCLA cohort consisted of 145 
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pancreatic adenocarcinoma patients with a mean survival time of 35 months, ranging from 
0.45 to 100 months. Overall, the neoplastic epithelial cells displayed varying degrees of 
PRELP protein staining, while peritumoral stromal cells were mostly negative with rare 
weak positivity seen in occasional cases.The IHC scoring was therefore based on tumor cell 
staining. The survival time of the patients was blinded at the time of IHC scoring.Three out 
of the 145 specimens were excluded from the analysis because of an absence of tumor cells 
in the tissue cores available for analysis. The 142 cases were separated into tertiles based on 
the IHC scores, with top two tertiles being the high PRELP group, and the bottom tertile 
being the low PRELP group. No significant associations were noted between PRELP 
abundance and baseline clinicopathologic parameters including age, gender, tumor grade, 
tumor size, tumor stage, lymph node involvement, and tumor margin status. Neoplastic cells 
from tumor tissue of patients with longer survival displayed higher intensity PRELP protein 
staining than the tumor tissue of patients with shorter survival (Figure 3B and 3C). Kaplan-
Meier survival analysis suggested that patients with high PRELP staining had significantly 
better survival time (p=0.013, Figure 4A). Overall mean survival time for patients with high 
versus low PRELP staining was 40.9 versus 27.0 months, respectively. Univariate Cox 
regression analysis confirmed that high abundance of PRELP was significantly associated 
with improved overall survival (hazard ratio=0.61, 95% confidence interval 0.42-0.91, 
p=0.015). In multivariate Cox analysis, high PRELP abundance fell just short of statistical 
significance (HR=0.68, 95% CI 0.46-1.02) in a model with other significant pathologic 
variables including high histologic grade (HR=1.51, 95% CI 1.02-2.23), positive lymph 
node involvement (HR=1.63, 95% CI 1.12-2.39) and low pathologic T stage (HR=0.62, 95% 
CI 0.41-0.92) (Table 3A).
Correlation of 40S ribosomal protein S8 (RPS8) with shorter pancreatic cancer survival
Another protein candidate selected for IHC analysis was the 40S ribosomal protein S8 
(RPS8). Overall, RPS8 protein was 7.7 fold more abundant in the tumors from the STS 
group compared to the VLTS group according to the proteomics data. At the individual 
sample level, the RPS8 protein was detected in all 5 STS tumor samples, but in only one 
VLTS tumor sample (Figure 3D). The spectral counts of RPS8 were significantly higher in 
STS than VLST (p=0.019). Moreover, protein network analysis revealed that a large group 
of ribosomal and ribosomal-associated proteins extensively interact with RPS8 
(Supplemental Figure 2). The many proteins from this group were elevated in the tumor 
tissue of STS patients and highly interactive among themselves, implying that pathways 
impacting RPS8 and associated ribosomal proteins may play a role in pancreatic cancer 
survival.
IHC analysis was performed on the TMA of UCLA PDAC cohort and the scoring was based 
on tumor cell staining. The 141 scorable cases were separated into quartiles based on the 
IHC scores, with top quartile being the high RPS8 group, and the bottom three quartiles 
being the low RPS8 group. No significant associations were noted between RPS8 abundance 
and baseline clinicopathologic parameters as mentioned above. Kaplan-Meier survival 
analysis suggested that patients with low RPS8 staining had significantly longer survival 
time (p=0.011, Figure 4B). Representative IHC staining of tumor tissues from patients with 
longer survival and shorter survival were presented in Figure 3E and 3F, respectively. 
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Overall mean survival time for patients with high RPS8 staining was 23.8 compared to 39.3 
months for those patients with low RPS8. Univariate Cox regression analysis confirmed that 
high abundance of RPS8 was significantly associated with poor overall survival (hazard 
ratio=1.79, 95% confidence interval 1.13-2.82, p=0.012). Multivariate Cox analysis also 
confirmed that high RPS8 abundance was significantly associated with shorter survival time 
(HR=1.81, 95% CI 1.14-1.2.86) in a model with other significant pathologic variables 
incorporated, including high histologic grade (HR=1.79, 95% CI 1.22-2.63), and positive 
lymph node involvement (HR=1.55, 95% CI 1.05-2.27) (Table 3B).
Combination of PRELP and RPS8
To evaluate the combination of PRELP and PRS8 for survival prediction, we used either 
“High-RPS8 and Low-PRELP” or “Low-RPS8 and High-PRELP” for Kaplan-Meier 
survival analysis and multivariate COX analysis. As shown in Figure 4C, “High-RPS8 and 
Low-PRELP” was associated with worse survival (p=0.004). Overall mean survival time for 
cases with “High-RPS8 and Low-PRELP” status was 16.9 months, while mean survival time 
for cases with other staining status was 38.0 months. In a separate survival analysis, “Low-
RPS8 and High-PRELP” was associated with markedly improved survival (p=0.003, Figure 
4D). Overall mean survival time for cases with “Low-RPS8 and High-PRELP” status was 
43.1 months, while mean survival time for cases with other staining status was 27.1 months.
Multivariate Cox regression analysis was then used to test the combination of either “High-
RPS8 and Low-PRELP” or “Low-RPS and High-PRELP” along with other variables from 
baseline clinicopathologic parameters. As shown in Table 3C and 3D, both “High-RPS8 and 
Low-PRELP” and “Low-RPS and High-PRELP” were significantly associated with survival 
time (HR=2.69 and HR=0.64 respectively). Factors including high histologic grade and 
positive lymph node involvement continued to be significant pathologic variables in these 
multivariate analyses. The combination of “High-RPS8 and Low-PRELP” displayed 
improved prognostic value over any single marker alone or the combination of “Low-RPS 
and High-PRELP”.
Knockdown of galectin-1 in pancreatic cancer associated fibroblasts dramatically reduced 
cell migration and invasion
In this study we observed that galectin-1 was 7 fold higher in the STS group compared to 
VLTS group, confirming our previous finding that the abundance of galectin-1 was aversely 
associated with survival in resectable pancreatic cancer13. Since galectin-1 is primarily 
expressed in cancer-associated fibroblasts, we sought to determine its functional role in 
influencing cancer aggressiveness using cancer-associated fibroblasts (CAF). We first 
generated stable clones of CAF with galectin-1 knocked down via several distinct galectin-1 
shRNA constructs. One of such constructs (shRNA1) resulted in substantial reduction (86% 
reduction) of galectin-1 abundance as confirmed by fluorescence immunostaining and 
western blot (Figure 5A-C). In the wound healing assay, control CAF cells usually closed 
the wound gap within 24 hours post-wounding (Figure 5D). In contrast, CAF with LGALS1 
shRNA migrated much slower, with a still visible gap after 24 hours post-wounding. To test 
for invasion, the CAF control and CAF LGALS1 shRNA cells were placed into transwell 
coated with Matrigel. After 24 hours, the cell number of the CAF LGALS1shRNA cells that 
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invaded though the transwell was significantly reduced (Figure 5E, p <0.001) compared to 
parental CAF cells. These observations suggested that knockdown of galectin-1 in 
pancreatic cancer associated fibroblasts can dramatically reduce cell migration and invasion 
capabilities.
Discussion
PDACs typically have very exuberant stroma, which can make up to 90% of the tumor mass 
that surrounds the tumor cells, playing important mechanistic roles in the progression of 
PDAC. In our study, we used microscopic macro-dissection to dissect the tissue areas with 
highest neoplastic cellularity (including both PDAC epithelium and associated stroma), 
while excluding areas of non-neoplastic pancreatic acinar tissues and inflammatory 
infiltrates. Therefore, the tissues we analyzed were primarily comprised of neoplastic cells 
and stromal cells. While the mass spectrometry data may not provide us enough information 
to completely decode a signal from a heterogeneous population of cells, it allowed us to 
identify proteins with an overall abundance change in the tumor tissues. Such approach has 
pros and cons, reflecting our emphasis on biomarker discovery and acquisition of 
information regarding tumor microenvironment. The subsequent IHC analysis permitted us 
to further examine a particular protein candidate for its distribution among different cell 
types and ECM. It is also notable that very long term survivors of pancreatic cancer are rare; 
and inclusion of only pathologically and clinically well-defined cases compromised the 
number of the specimens available for our initial proteomics discovery. Nonetheless, the 
protein profiling data was informative; and the IHC validation of selected protein candidates 
using expanded number of PDAC cases (independent cohort) with various overall survival 
times provided a diagonal confirmation on the selected targets.
The comparison of pancreatic tumor tissues of resectable PDAC patients with very long 
survival times versus short survival times revealed a group of differentially expressed 
proteins associated with VLTS and STS patients, respectively, including PRELP and 
LGALS1 which were also evidenced in our previous work13. The most enriched functional 
cluster of STS associated proteins was Cytoskeleton, which is a dynamic cellular structure 
that maintains cell shape, adhesion, motility, as well as intracellular trafficking and 
signaling. It is now well recognized that tumorigenesis is associated with altered cytoskeletal 
proteins and that these proteins clearly play a role in the metastatic process 30, 31. We also 
noticed that several proteins associated with epithelial-mesenchymal transition (EMT), 
which plays a pivotal role in the tumor progression, were up-regulated in the STS compared 
to VLTS, including laminin, integrin beta-1, smooth muscle actin and MMP2. Two classic 
mesenchymal markers (vimentin and fibronectin), however, did not display significantly 
different abundance between VLTS and STS – which may be due to various factors and 
requires further confirmation.
The second enriched cluster for STS proteins was Protein synthesis /Ribonucleoprotein 
Complex/RNA Processing, reflecting the underlying active cellular biosynthesis that 
contributes to tumor growth. The third and common enriched cluster for both the STS 
associated proteins and the VLTS associated proteins was Generation of Precursor 
Metabolites and Energy. In proliferating cells, cellular metabolism provides both energy 
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needed for maintaining homeostatic processes and the precursors for macromolecular 
biosynthesis needed for proliferation. Cancer cells have dysregulated cellular energy 
metabolism. More than fifty years ago, Warburg demonstrated that cancer cells had 
unusually high glycolytic activity even in aerobic condition (Warburg Effect). Today it is 
generally regarded that cancer cells must rewire their metabolic programming in order to 
meet the demands of high energy and anabolic processes necessary for rapid growth. In our 
study, we observed that differential metabolism-related proteins (including metabolites, 
energy generating, glycolysis and TCA cycle) in the pancreatic cancer tissues were related 
to patient survival, suggesting that metabolic programming differs between pancreatic 
cancer patients with long-term survival and patients with short-term survival. Our 
observation supports the notion that tumors display heterogeneity in regards to their 
metabolic reprogramming32. Such metabolic reprogramming could be driven by both 
genetic (mutation) and non-genetic (tumor microenvironment) factors32, and could 
ultimately influence cancer survival.
Using IHC analysis on tissue microarray, we demonstrated that the PRELP abundance level 
was statistically associated with longer survival. PRELP is a proteoglycan found in the 
extracellular matrix. It binds perlecan and collagens and may function as a basement 
membrane anchor33. PRELP was found as one of the predictor gene signatures for brain 
tumors34. Additionally, PRELP can act as a NF-kappaB inhibitor impairing 
osteoclastogenesis 35. NF-kappaB is constitutively overexpressed in PDAC and its inhibition 
is a mandate for a new class of therapeutic drugs. Related to this observation, we also 
discovered that copines were overexpressed in the VLTS proteomic analysis. While the 
functional role of these Ca+ dependent membrane proteins is mostly unknown, copine-1 has 
been identified as another NF-kappaB inhibitor36. These combined observations suggest that 
repression of NF-kappaB could prolong survival in pancreatic cancer.
RPS8,a component of the ribosomal 40S subunit, was found to be inversely associated with 
survival in our study. Increased abundance of ribosomal genes including RPS8 was 
previously observed in colorectal tumors and colon polyps compared to matched normal 
colonic mucosa37. Studies also suggested that the abundance of RPS8 could determine the 
susceptibility of pancreatic cancer cells to gemcitabine treatment38. In the current study, we 
observed that higher abundance of RPS8 was associated with worse survival of pancreatic 
cancer. The combination of “High-RPS8 and Low-PRELP” provided improved prognostic 
value over RPS8 or PRELP alone.
A third protein related to pancreatic cancer survival was galectin-1. Up-regulation of 
galectin-1 has been documented for several tumor types in both the cancerous epithelial 
cells, as well as in the stroma adjacent to cancer cells39. Galectin-1 is a β-galactoside 
binding protein that is involved in immunosuppression and angiogenesis. Recent study 
suggests that galectin-1 could bind to glycosylated VEGFR in endothelial cells to promote 
angiogenesis in the absence of VEGF40. In the comparison of VLTS and STS of pancreatic 
cancer patients, we consistently observed that the lower abundance of galectin-1 in tumor 
tissues of the VLTS patients.IHC analysis indicated that galectin-1 was mainly detected in 
the CAF, but not in cancer epithelial cells13. Knock-down of galectin-1 gene in CAF cells 
significantly reduced cell migration and invasion of CAF, implicating its potential role in 
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tumor microenvironment contributing to pancreatic cancer progression and metastasis. 
Inhibition of galectin-1 as a potential therapeutic target has been evaluated in breast, colon, 
ovary, and prostate cancers 41. Our results further support that gelactin-1 could be a potent 
target for pancreatic cancer therapy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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List of Abbreviation
PDAC pancreatic ductal adenocarcinoma
VLTS very long-term survivors
STS short-term survival patients
IHC Immunohistochemistry
TMA tissue microarray
FFPE formalin-fixed paraffin-embedded
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Table 1
Clinicopathologic and survival information for the PDAC cases.
Cohort VLST STS UCLA TMA cohort
No. of cases 5 5 145
Age
<60 2 1 49
≥60 3 4 96
Gender
M 3 2 75
F 2 3 70
Survival time
Mean >10 yrs 10 months 34.7 months
Range >10yrs 6-14 months 0.49-100 months
Tumor size
<3cm 2 1 87
≥3cm 3 4 58
Tumor grade
Low grade (G1-2) 0 0 83
High grade (G3-4) 5 5 62
AJCC stage
1 1 40
2 4 105
unknown 0 5 0
Lymph nodes
negative 2 3 69
positive 3 2 76
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Table 3
Multivariate COX regression analysis evaluating PRELP and RPS8 staining with PDAC survival.
A. PRELP Bottom Tertile Staining in Multivariate Analysis
Variable P value HR 95% CI Lower 95%CI Upper
High grade 0.039 1.511 1.022 2.235
pN1 0.012 1.632 1.116 2.388
BottomTertile_PRELP 0.062 0.684 0.459 1.019
B. RPS8 Top Quartile Staining in Multivariate Analysis
Variable P value HR 95% CI Lower 95%CI Upper
Female 0.081 1.398 0.96 2.037
High Grade 0.003 1.788 1.217 2.627
pN1 0.026 1.546 1.053 2.272
TopQuartile_RPS8 0.012 1.806 1.139 2.863
C. Combination of “LowRPS8 and HighPRELP” vs. all others
Variable P value HR 95% CI Lower 95%CI Upper
Female 0.074 1.407 0.967 2.049
High grade 0.035 1.521 1.03 2.247
pN1 0.024 1.555 1.059 2.283
LowRPS8_HighPRELP 0.024 0.638 0.432 0.942
D. Combination of “HighRPS8 and LowPRELP” vs. all others
Variable P value HR 95% CI Lower 95%CI Upper
High grade 0.008 1.686 1.146 2.481
pN1 0.009 1.682 1.136 2.49
HighRPS8_LowPRELP 0.001 2.685 1.464 4.924
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